LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features
Tiangen Chang(National Institutes of Health), Eytan Ruppin(National Institutes of Health)
Cited by 103
Related Papers
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
|Nature Medicine|2018|813
Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma
|Nature Communications|2020|156